Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024. Merck’s agreement with the ADAP Crisis Task Force addresses persistent budgetary barriers and expands treatment options for uninsured and underserved patients who maintain viral suppression.

Dual Enzyme Blockade in Switch Therapy

The regimen combines doravirine, a non-nucleoside reverse transcriptase inhibitor, with islatravir, a next-generation nucleoside analog, to interrupt HIV replication at two distinct points. Data from switch trials 051 and 052 confirmed sustained viral control after patients transitioned from prior therapy, supporting its labeled use in adults without treatment failure or resistance to doravirine.

Clinical monitoring showed low rates of treatment-emergent adverse events—primarily diarrhea, dizziness, fatigue, headache, and modest weight gain—each occurring in 3 percent or fewer participants. One case of acute immune thrombocytopenia resolved after discontinuation and supportive care, while broader laboratory trends remained comparable between study arms.

Long-Acting Innovation and HIV Treatment Access

These structured access mechanisms, paired with patient support services that clarify coverage and reduce out-of-pocket costs, directly strengthen HIV Treatment Access for vulnerable populations. Merck’s ongoing development of once-weekly and once-monthly antiretroviral combinations signals a clear shift toward convenient dosing that could further close gaps in long-term HIV care.